Orion Exits Neuro To Concentrate On Cancer And Pain
Finnish Firm Refocuses R&D Strategy
Executive Summary
Rather than making smaller investments in a larger number of areas, Orion is putting its research euros into oncology and pain management and pulling its Parkinson’s and Alzheimer’s projects, as well as its rare disease programs.
You may also be interested in...
Finance Watch: Public Markets Open Back Up For Biopharma Offerings
Public Company Edition: An IPO and three big follow-on offerings hit the market but other public companies revealed plans to cut costs or reprioritize their R&D pipelines, signaling that uncertainty remains.
Bayer's Faith In Pharma Pipeline Paying Off
The German major has presented the latest developments in the ongoing transformation of its pharmaceuticals business, starting with the prostate cancer therapy Nubeqa which Bayer believes will be a €3bn drug, way up on its earlier estimate of €1bn.
Argenx Eyes Hat-Trick Of Successful Launches For Vyvgart After CHMP Thumbs-Up
Anant Murthy, general manager of Argenx Europe, tells Scrip that the commercial infrastructure is in place for Vyvgart to enjoy a strong launch for the rare neuromuscular disorder which will mirror those seen in the US and Japan.